Erlotinib/crizotinib dual resistant HCC827
Homo sapiens
source_name
Lung
cell line
NSCLC cell line HCC827
treatment
The erlotinib-resistant HCC827 cell population was treated with 2 µM erlotinib+0.2 µM crizotinib combination for 10 days to enrich for erlotinib/crizotinib dual-resistant subpopulations.
resistant to
2 µM erlotinib+0.2 µM crizotinib combination